EXTH-91. GALECTIN-3 INHIBITOR PAIRED WITH FOCAL LOW-INTENSITY NONINVASIVE TDCS CAN ACHIEVE MAXIMAL THERAPEUTIC BENEFIT IN CLINICALLY RELEVANT MENINGIOMA MOUSE MODELS

Abstract Atypical and anaplastic meningiomas (WHO Grade 2 WHO 3 respectively) represent a subgroup of that tend to have higher rates recurrence with associated’s morbidity mortality than the more common 1 meningiomas. Our laboratory data demonstrated galectin-3 (Gal-3), multifunctional β-galactoside-binding protein, is highly expressed in these meningioma subtypes as compared normal brain tissue. However, root profoundly immunosuppressive tumor microenvironment cells not fully understood. To address this, we used Gal-3 inhibitor TD 139 paired low-intensity non-invasive transcranial direct current stimulation (tDCS) suppress growth enhance immune response preclinical model. Treatment tDCS (50 mV/mm for 30 min) followed by mM TD139 induced cell death vitro human triple co-culture model but has no effect on mouse cortical neurons. Furthermore, inhibiting expression significantly decreased protein levels urokinase-type plasminogen activator receptor well phosphorylation Akt upregulates Bax expression. (1mg/kg per day 14 days) [350 μA (1 x min/day) 7 times (within Days) showed (∼60%) decrease MGS2 atypical orthotopic allograft (at Day 41). The percent survival tumor-bearing mice treated was an untreated or single treatment. Following plus treatment, our results significant via NDRG4 (Meningioma marker) were associated downregulation Ki-67 tumors. Based substantial preliminary data, believe this proposed translational work potential be effective combinational modality form treatment malignant